


# Forced Degradation of Atorvastatin by LCMS - AppNote

# **Separation of API from its Lactone Degradation Product**

Atorvastatin is separated from its main Degradation product in this Method with a simple linear Reversed Phase Gradient. With the use of LCMS, the identity of the Degradant can be confirmed from its m/z value. The Degradation is an intramolecular Fischer esterification, which is catalyzed under Acidic conditions.

Figure A shows the extracted Ion Chromatogram (EIC) corresponding to Atorvastatin for the Non-Degraded extract. Figures B and C show the EICs of Atorvastatin and the Lactone Degradant respectively for the Acid-Degraded extract.



Peaks:

1. Atorvastatin

2. Atorvastatin Lactone

## **Method Conditions**

Column: Cogent Bidentate C18™, 4µm, 100Å

**Catalog No.:** <u>40018-05P-2</u> **Dimensions:** 2.1 x 50mm

**Mobile Phase:** 

A: 50% DI Water / 50% Methanol / 10mM Ammonium Acetate B: 90% Acetonitrile / 10% DI Water / 10mM Ammonium Acetate

### **Gradient:**

Time (minutes)	%B
0	30
10	100
12	30

Flow rate: 0.4mL / minute

**Detection:** ESI — POS - Agilent 6210 MSD TOF Mass Spectrometer

Sample Preparation:

**Tablet Stock Solution:** A 40mg strength tablet was ground and added to a 100mL volumetric flask. A 50mL portion of Solvent B was added to the flask. The solution was vortexed 5 minutes, sonicated 5 minutes, and diluted to mark with Solvent A. It was then filtered through a 0.45µm Nylon Syringe Filter (MicroSolv Technology Corp.).

**Degraded Tablet Stock Solution:** A 40mg strength tablet was ground and added to a 100mL volumetric flask. A 50mL portion of Solvent B was added to the flask. It was then vortexed 5 minutes, sonicated 5 minutes, and diluted to mark with 3M HCl. It was then filtered through a 0.45μm Nylon Syringe Filter (MicroSolv Technology Corp.).

Fig. A: 10µL tablet stock diluted with 990µL 50:50 A:B

Fig. B and C: 10µL degraded tablet stock diluted with 990µL 50:50 A:B

Note: Atorvastatin is a competitive inhibitor of 3-Hydroxy-3-Methlyglutaryl Coenzyme A (HMG- CoA) Reductase, which Catalyzes the rate limiting step in Cholesterol Biosynthesis. As such, Atorvastatin is used to reduce plasma levels of low-density Lipoprotein (LDL) Cholesterol, which are known to contribute to the development of Atherosclerosis. Atorvastatin is currently marketed by Pfizer under the trade name Lipitor.



#### **Attachment**

No 126 Forced Degradation of Atorvastatin by LCMS pdf 0.1 Mb\_Download File

Printed from the Chrom Resource Center Copyright 2025, All Rights Apply **MicroSolv Technology Corporation** 9158 Industrial Blvd. NE, Leland, NC 28451 Tel: (732) 380-8900 Fax: (910) 769-9435

Email: customers@mtc-usa.com

Website: www.mtc-usa.com